AOL Web Search

  1. About 23,000 search results
  1. Web results:
  2. Tozadenant | C19H26N4O4S - PubChem

    Tozadenant | C19H26N4O4S | CID 11618368 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

  3. Tozadenant « New Drug Approvals

    Tozadenant, which works on brain receptors thought to regulate motor function, merits further study in future trials, Hauser said. In another study, Hauser looked at 321 patients with early stage Parkinson’s whose symptoms weren’t handled well by a medicine called a dopamine agonist, typically the first drug prescribed for Parkinson’s ...

  4. Tozadenant (SYN115) is an orally active, selective adenosine A2A receptor antagonist. In animal models of Parkinson’s disease, tozadenant improves motor neuron function.


  6. Tozadenant (SYN115) in patients with Parkinson's disease ...

    Tozadenant at 120 or 180 mg twice daily was generally well tolerated and was effective at reducing off-time. Further investigation of tozadenant treatment in phase 3 trials is warranted.

  7. Tozadenant|SYN115|CAS 870070-55-6 Buy Tozadenant from ...

    Tozadenant is an adenosine A 2A receptor antagonist, with K i of 11.5 nM on human A 2A and 6 nM on rhesus A 2A ....Quality confirmed by NMR,HPLC & MS.

  8. Safety and Efficacy Study of Tozadenant to Treat End of ...

    Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients Using Levodopa (TOZ-PD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for ...

  9. Acorda Provides Update on Tozadenant Development Program

    Acorda Therapeutics, Inc. today announced that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson’s disease.

  10. SYN115 is an orally administered, potent and selective inhibitor of the adenosine 2a (A2a) receptor that is being developed initially for the treatment of Parkinson’s disease, but may also have utility in other CNS disorders.

  11. Biotie Therapies - Wikipedia

    Biotie Therapies is a Finnish biotechnology and pharmaceutics company. The company's research and development is focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease.